Vaginal Estradiol Compassionate Use and Expanded Access: How to Get It Cheaper

Does vaginal estradiol need compassionate use or expanded access?

Expanded access is not needed to obtain estradiol vaginal cream 0.01% for its labeled use. The product is approved for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, and its label sets out the indication, dosing, contraindications and adverse reactions [1]. This page covers the cream only; other vaginal estradiol products are separate products. Compounded estradiol is the unapproved version that comes up in access conversations, and FDA has addressed compounded drugs directly [2].

What FDA says about compounded estradiol

Compounded estradiol is not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. It says they should only be used in patients whose medical needs cannot be met by an FDA-approved drug, such as a patient with an allergy to a dye in an approved product [2]. FDA's compounding guidance does not address cost. A generic drug is not the same thing as a compounded one: FDA approves generics, and a compounded drug is not approved [2].

FDA also describes the risks of poor compounding practice, which can produce contamination or a drug that contains too much or too little active ingredient, and says this can lead to serious injury and death [2]. FDA says drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements. Drugs compounded by a pharmacist in a state-licensed pharmacy under the applicable legal conditions are not subject to those requirements, though other federal law still applies [2].

What the approved cream's label covers

The label lists estradiol vaginal cream 0.01% for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. It gives a usual dosage of 2 to 4 g daily for one or two weeks, then half the initial dose for a similar period, with a maintenance dose of 1 g one to three times a week once the vaginal mucosa is restored [1].

The label says systemic absorption may occur with the cream and that the warnings, precautions and adverse reactions associated with oral estrogen treatment should be taken into account [1]. Its contraindications are:

• undiagnosed abnormal genital bleeding
• known, suspected or past breast cancer
• known or suspected estrogen-dependent neoplasia
• active DVT or PE, or a history of these
• active arterial thromboembolic disease such as stroke or MI, or a history of these
• known anaphylaxis or angioedema to the cream
• known liver dysfunction or disease
• protein C, protein S or antithrombin deficiency, or another known thrombophilic disorder
• known or suspected pregnancy [1]

Among the adverse reactions the label lists are application-site reactions of vulvovaginal discomfort, including burning and irritation, and genital itching [1].

The boxed warning is still on this label

The estradiol vaginal cream 0.01% label effective April 13, 2026 carries a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia [1]. FDA requested labeling revisions on November 10, 2025 and announced the first six approved updated labels on February 12, 2026. That group included the Estring vaginal ring, not this cream [3][4][5].